Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis

Key Inclusion Criteria: * Male and female subjects ages 18 to 80 years of age (both inclusive) * Pulmonary sarcoidosis disease duration of ≥1 year * Clinically active disease demonstrated either by a biopsy (any organ) or by bronchoalevolar lavage (lymphocytosis \>15%, CD4+/CD8+ ration\>3.5, CD103+/CD4+/CD4+ ratio \<0.2). Patients must also have all of the following criteria: 1. MMRC dyspnea scale ≥1 2. Threshold FVC 50 - 90% of predicted 3. Evidence of parenchymal lung involvement by HRCT at screening or by historical radiological evidence (e.g. CT, MRI or x-ray) Key Exclusion Criteria: * Treated pulmonary hypertension * Previous exposure to concomitant treatment according to the following criteria: 1. Prednisone \>15 mg/day or changes in prednisone dose in the 8 weeks prior to screening 2. More than one immune-modulator (i.e., methotrexate, azathioprine, leflunomide, hydroxychloroquine) or changes in their dosing levels within 12 weeks of randomization. 3. Mycophenolate use within 12 weeks of randomization * Prior treatment with any biologic drug targeting the immune system within 180 days of randomization or history of any previous use of rituximab * History of bleeding disorder * Forced vital capacity (FVC) \<50% of predicted * Extra-pulmonary sarcoidosis as primary treatment indication (e.g., involving brain, heart, eye and renal disease with significant hypercalcemia) * Any conditions or significant medical problems which in the opinion of the investigator immune-compromise the patient and/or places the patient at unacceptable risk for immunomodulatory therapy, such as: 1. Absolute neutrophil count (ANC) \<LLN (1,500/μl) 2. Thrombocytopenia CTCAE v4.03 Grade 1: Platelets \<LLN (75.0 x 10exp9/L) 3. Any active or recurrent bacterial, fungal (with exception of onychomycosis) or viral infection 4. Presence of human immunodeficiency virus (HIV) infection, hepatitis B or hepatitis C infections based on screening lab results 5. Presence of active or latent tuberculosis (Tb). If historical Tb result is available, Tb status needs to be confirmed pre-randomization as determined by screening laboratory measurements. 6. Clinical evidence or history of multiple sclerosis or other demyelinating diseases, or Felty's syndrome * Live vaccinations within 3 months prior to the start of the trial * Current severe progressive or uncontrolled disease which in the judgment of the clinical investigator renders the patient unsuitable for the trial * Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using methods of contraception defined in the protocol for the study.